Then in mid-November, Werner Wenning, the CEO, said that the company would accept a minority role in any future marriage of its pharmaceutical business, increasing the chances that someone will make a serious offer for the inventor of aspirin and for its extensive European sales network.

FORBES: Bayer backs down